<DOC>
	<DOCNO>NCT00278707</DOCNO>
	<brief_summary>The purpose study determine whether oral supplementation glyceryl triacetate improve clinical prognosis Canavan Disease .</brief_summary>
	<brief_title>GTA-Glyceryltriacetate Canavan Disease</brief_title>
	<detailed_description>Canavan Disease cause deficiency enzyme name Aspartoacylase ( ASPA ) . This disease devastating , progressive disease available treatment . As result ASPA deficiency , high level N-acetylaspartate ( NAA ) low level L-aspartate acetate . We hypothesize one function ASPA provide sufficient level acetate CNS myelinization . For reason , offer supplement acetate level oral administration glyceryl triacetate ( GTA ) . Such treatment must offer patient age 18 month , prior termination CNS myelinization . 1 . Two patient , age less 15 month , receive daily dos oral GTA 2 . The daily dose increase incrementally maintenance dose reach . This do close monitoring patient , include periodic blood gas sampling . 3 . GTA show cause know toxicity , accord Cosmetic Ingredient Review Expert Panel ( Fiume , 2003 ) .</detailed_description>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Canavan Disease</mesh_term>
	<criteria>Age 15 month Biochemically diagnose Canavan Disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Canavan Disease</keyword>
	<keyword>Aspartoacylase Deficiency</keyword>
	<keyword>NAA</keyword>
	<keyword>Acetate</keyword>
	<keyword>Glyceryltriacetate</keyword>
</DOC>